PRZOOM - /newswire/ -
Palo Alto, CA, United States, 2007/07/23 - New analysis from Frost & Sullivan, U.S. COPD: Therapeutic Overview and Patient Outlook, provides an overview and patient forecasts for COPD, chronic bronchitis, and emphysema in the United States from 2003 to 2013.
The U.S chronic obstructive pulmonary disease or COPD market has seen significant expansion in recent times, largely as a result of the rising number of both current and former smokers. Growth in the older age segments of the population and increased screening for the disease are also contributing factors, but patient non-compliance remains a critical issue as current treatment options are complicated and burdensome. Novel products requiring lower dosage amounts have the potential to address compliance issues, while also opening up new opportunities in the market.
New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. COPD: Therapeutic Overview and Patient Outlook, provides an overview and patient forecasts for COPD, chronic bronchitis, and emphysema in the United States from 2003 to 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. COPD: Therapeutic Overview and Patient Outlook, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.
“Smoking is the prime cause of COPD and high incidences of smoking are driving COPD prevalence rates in the United States,” notes Frost & Sullivan Research Analyst Katheryn Symank.” Smoking rates have leveled off after declining steadily since 1997. This has the potential to positively impact revenues by expanding the COPD patient population”.
Medical figures indicate that almost 80 to 90 percent of COPD patients are either current smokers or those that have given up the habit. With an estimated 45.0 million current smokers and 45.9 million former smokers in the United States, the COPD patient population is almost certain to expand in the years to come. This could increase the number of people requiring treatment for the disease and subsequently maintain positive revenue growth.
However, the high rate of patient noncompliance is a critical challenge for the U.S. COPD market, hindering its expansion. Patients often find that their treatment regimens are demanding and difficult to follow because they involve several different medications that must be taken multiple times per day. Due to this, they frequently end up taking their medications less frequently or stop taking them altogether. All the more, medications used to treat COPD come with side effects which often discourage patients from long term use of these products.
“While it is estimated that the prescription compliance rate for COPD patients is under 50 percent, many experts believe that actual compliance rates are much lower,” says Symank. “For example, in The Lung Health Study, it was determined that for bronchodilators, compliance as measured by canister weight was actually 10 percent lower then reported compliance rates. Another study found that compliance rates for patient use of inhaled corticosteroids were as low as 18 percent.”
The development of new products that require less frequent dosing could provide new treatment options that could increase patient compliance. Additionally, such products could also create new growth opportunities companies while expanding the overall market.
U.S. COPD: Therapeutic Overview and Patient Outlook is part of the Pharmaceuticals and Biotechnology Growth Partnership Service, which also includes research in the following: U.S. Generic Pharmaceuticals Market Outlook, U.S. Multiple Myeloma Market, and U.S. Opioid and Non-opioid Pain Management Pharmaceuticals Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.